Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reporte...

Full description

Bibliographic Details
Main Authors: Hampig Raphael Kourie, Joelle Antoun, Elie El Rassy, Marc Rassy, Claude Sader-Ghorra, Joseph Kattan
Format: Article
Language:English
Published: Elsevier 2015-09-01
Series:Journal of Bone Oncology
Subjects:
Osteonecrosis of the jaw
Zoledronic acid
Bone loss
Aromatase inhibitor
Early breast cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137415300105

Internet

http://www.sciencedirect.com/science/article/pii/S2212137415300105

Similar Items